The same team validated the use of anti-mesothelin IL-7/CCL19-producing human CAR-T cells in a preclinical model of orthotopic pre-established malignant mesothelioma, as well as in patient derived xenograft (PTX) models of mesothelin-positive pancreatic cancer. The gene discussed is CCL19; the disease is malignant mesothelioma.